跳至主要内容
临床试验/NCT04389606
NCT04389606已完成不适用

Follow-up Study of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants

ByHeart54 个研究点 分布在 1 个国家目标入组 311 人开始时间: 2020年5月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
ByHeart
入组人数
311
试验地点
54
主要终点
Weight Gain Velocity

研究概览

简要总结

The purpose of this two-month follow-up study is to continue to follow growth, safety, and other health outcomes of infants fed a new infant formula for term infants or comparator formula. A reference group of human milk-fed infants will also be followed. This study is designed in accordance with Good Clinical Practice guidelines.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
16 Weeks 至 19 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • Subjects who enrolled and completed the previous phase of the clinical trial: NCT04218929 "Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants"

排除标准

  • Subjects who did not enroll in the previous phase of the clinical trial: NCT04218929 "Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants"

结局指标

主要结局

Weight Gain Velocity

时间窗: up to 24 weeks

G/D

次要结局

  • Weight Measures(20 weeks, 24 weeks)
  • 72-hr record of formula intake at each study visit(20 weeks, 24 weeks)
  • Human milk composition (concentrations of proteins, lipids, carbohydrates, vitamins, and minerals(24 weeks)
  • Weight for length Z-scores(20 weeks, 24 weeks)
  • Parent report of infant stool frequency at each study visit(20 weeks, 24 weeks)
  • Weight for age Z-scores(20 weeks, 24 weeks)
  • Stool microbiome(24 weeks)
  • Head Circumference Measures(20 weeks, 24 weeks)
  • Length for age Z-scores(20 weeks, 24 weeks)
  • Blood concentrations of amino acids (umol/L)(24 weeks)
  • Length Measures(20 weeks, 24 weeks)
  • Length Gain Velocity(20 weeks, 24 weeks)
  • Head circumference for age Z-scores(20 weeks, 24 weeks)
  • Blood concentrations of Interleukin-6 (pg/mL), Interleukin-10 (pg/mL), and tumor necrosis factor-alpha (pg/mL)(24 weeks)
  • Medically-diagnosed adverse events collected throughout the study period(16-24 weeks)
  • Parent rating of infant stool consistency at each study visit(20 weeks, 24 weeks)
  • Parent report of infant disposition (fussiness, crying, gas, spit up, Infant Characteristics Questionnaire) at each study visit(20 weeks, 24 weeks)
  • Stool metabolome(24 weeks)

研究者

发起方
ByHeart
申办方类型
Industry
责任方
Sponsor

研究点 (54)

Loading locations...

相似试验

Follow-up Study of Growth, Safety, and Efficacy of... | 临床试验